Synthetic immunoadjuvants: application to non-specific host stimulation and potentiation of vaccine immunogenicity.
It is well recognized that immunoadjuvants mainly play two roles; non-specific stimulation of host resistance against infections and cancer, and the potentiation of vaccine immunogenicity. This article reviews the recent results of the development of synthetic immunoadjuvants in our laboratory with special reference to muramyldipeptide (MDP), trehalose dimycolate (TDM), lipid A, chitin and their related compounds. The usefulness of MDP derivative MDP-Lys(L18), which has recently gone on the market as a haematopoietic agent for restoration of leukopenia in cancer patients treated with radiotherapy and chemotherapy, is reviewed. The various approaches to application of synthetic immunoadjuvants to the potentiation of vaccine immunogenicity, including adjuvant formulation, are also discussed.
Azuma
I
I
Institute of Immunological Science, Hokkaido University, Sapporo, Japan.
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives / Q000276:immunology; D000276:Adjuvants, Immunologic / Q000138:chemical synthesis; D000595:Amino Acid Sequence; D000818:Animals; D002686:Chitin / Q000276:immunology; D003311:Cord Factors / Q000276:immunology; D004337:Drug Carriers; D005544:Forecasting; D006801:Humans; D007113:Immunity, Innate; D007239:Infections; D008050:Lipid A / Q000276:immunology; D008969:Molecular Sequence Data; D014612:Vaccines / Q000276:immunology*
D000276:Adjuvants, Immunologic; D003311:Cord Factors; D004337:Drug Carriers; D008050:Lipid A; D014612:Vaccines; D002686:Chitin; D000119:Acetylmuramyl-Alanyl-Isoglutamine; C044706:B 30-muramyl dipeptide; C036866:romurtide